Detection of the Mr 110,000 Lung Resistance-related Protein LRP/MVP with Monoclonal Antibodies

The Mr 110,000 lung resistance-related protein (LRP), also termed the major vault protein (MVP), constitutes >70% of subcellular ribonucleoprotein particles called vaults. Overexpression of LRP/MVP and vaults has been linked directly to MDR in cancer cells. Clinically, LRP/MVP expression can be o...

Full description

Saved in:
Bibliographic Details
Published inThe journal of histochemistry and cytochemistry Vol. 49; no. 11; pp. 1379 - 1385
Main Authors Schroeijers, Anouk B, Scheffer, George L, Reurs, Anneke W, Pijnenborg, Adriana C.L.M, Abbondanza, Ciro, Wiemer, Erik A.C, Scheper, Rik J
Format Journal Article
LanguageEnglish
Published Los Angeles, CA Histochemical Soc 01.11.2001
SAGE Publications
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The Mr 110,000 lung resistance-related protein (LRP), also termed the major vault protein (MVP), constitutes >70% of subcellular ribonucleoprotein particles called vaults. Overexpression of LRP/MVP and vaults has been linked directly to MDR in cancer cells. Clinically, LRP/MVP expression can be of value to predict response to chemotherapy and prognosis. Monoclonal antibodies (MAbs) against LRP/MVP have played a critical role in determining the relevance of this protein in clinical drug resistance. We compared the applicability of the previously described MAbs LRP-56, LMR-5, LRP, 1027, 1032, and newly isolated MAbs MVP-9, MVP-16, MVP-18, and MVP-37 for the immunodetection of LRP/MVP by immunoblotting analysis and by immunocyto- and histochemistry. The availability of a broader panel of reagents for the specific and sensitive immunodetection of LRP/MVP should greatly facilitate biological and clinical studies of vault-related MDR.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1554
1551-5044
DOI:10.1177/002215540104901106